Axim Biotechnologies Inc
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin A… Read more
Axim Biotechnologies Inc (AXIM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.065x
Based on the latest financial reports, Axim Biotechnologies Inc (AXIM) has a cash flow conversion efficiency ratio of 0.065x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-673.59K) by net assets ($-10.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Axim Biotechnologies Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Axim Biotechnologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Axim Biotechnologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Axim Biotechnologies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Total Helium Ltd
OTCQB:TTLHF
|
0.000x |
|
GlucoTrack Inc
NASDAQ:GCTK
|
-1.680x |
|
Anacomp Inc
PINK:ANMP
|
0.282x |
|
Gulf & Pacific Equities Corp
V:GUF
|
0.042x |
|
AGILENT TECH (AG8.SG)
STU:AG8
|
0.077x |
|
Mlabs Systems Bhd
KLSE:0085
|
-0.346x |
|
Black Widow Resources Inc
V:BWR
|
0.017x |
|
PENTAL LTD
F:81B
|
N/A |
Annual Cash Flow Conversion Efficiency for Axim Biotechnologies Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Axim Biotechnologies Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-10.42 Million | $-855.06K | 0.082x | -39.03% |
| 2023-12-31 | $-7.66 Million | $-1.03 Million | 0.135x | -68.23% |
| 2022-12-31 | $-4.83 Million | $-2.04 Million | 0.424x | -60.17% |
| 2021-12-31 | $-2.34 Million | $-2.49 Million | 1.064x | +151.79% |
| 2020-12-31 | $1.57 Million | $-3.22 Million | -2.054x | -376.56% |
| 2019-12-31 | $-6.76 Million | $-5.02 Million | 0.743x | -6.79% |
| 2018-12-31 | $-6.08 Million | $-4.85 Million | 0.797x | +62.45% |
| 2017-12-31 | $-6.28 Million | $-3.08 Million | 0.490x | -10.13% |
| 2016-12-31 | $-2.37 Million | $-1.29 Million | 0.546x | -39.90% |
| 2015-12-31 | $-1.70 Million | $-1.54 Million | 0.908x | +55.54% |
| 2014-12-31 | $-580.72K | $-339.00K | 0.584x | +66.04% |
| 2013-12-31 | $-93.92K | $-33.02K | 0.352x | +107.83% |
| 2012-12-31 | $-4.70K | $21.11K | -4.492x | -1235.43% |
| 2011-12-31 | $10.21K | $4.04K | 0.396x | -- |